Dabrafenib (GSK2118436)

Catalog No.S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.

Size Price Stock Quantity  
In DMSO USD 180 In stock
USD 90 In stock
USD 130 In stock
USD 170 In stock
USD 270 In stock
USD 400 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

    Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

  • The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

    Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
Targets
B-Raf (V600E) [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
C-Raf [1]
(Cell-free assay)
0.8 nM 3.2 nM 5.0 nM
In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M1u4PGtqdmG|ZTDBd5NigQ>? MlHpTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd{B1[WepZXSgRk1T[WZiVk[wNGUhdXW2YX70JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[29vZYjwdoV{e2mwZzDDSGM{PyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBjcW:2aX75cIF1\WRvTVXLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG|c3H5JJdqfGhiSVO1NEBw\iByLkCwNFch|ryP MWiyOFkxODZ5Mx?=
SK-MEL-28 MlrJT4lv[XOnIFHzd4F6 NX3XV|dUOSCq NXP6eWFZUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSgbY4hcHWvYX6gV2suVUWOLUK4JINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEWUSzDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB2IN88US=> MYiyOFkxODZ5Mx?=
HepG2 NGXRbVJMcW6jc3WgRZN{[Xl? M2HtNWlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIFXST{BxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC0JO69VQ>? MkfhNlQ6ODB4N{O=
COLO205 NYXTbVljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjydXFKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:yNFUh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCwMlAxPyEQvF2= MkD2NlQ6ODB4N{O=
HepG2 NHX6dYFHfW6ldHnvckBCe3OjeR?= NYr4bYMyPDVibXnu MYnEUXNQ NGHySWhKdmirYnn0bY9vKG:oIFHsb|UhcW5iVFfGMYJmfGFvc4TpcZVt[XSnZDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVbXHkNkBxcG:|cHjvdplt[XSrb36geJJm[XSnZDDmc5IhPDVibXnud{BxemmxcjD0c{BVT0ZvYnX0ZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA3OCCvaX7zJIJ6KG:meYPz[Zkh[myxdDDzZ4FvdmW{IHHuZYx6e2m|IIfpeIghUUN3MDDv[kA{NjdizszN MYiyOFkxODZ5Mx?=
HFF NUjjeZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL1OmlFOTBizszN MkTsO|IhcA>? NH6yNpRFVVOR Ml3RTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKGi3bXHuJGhHTiClZXzsd{Bp[XKkb4Lpcochf2muZDD0fZBmKEJvUnHmJJdqfGhiSVO1NEBw\iB|IN88US=> NH;vZmozOzh2NECzPC=>
SK-MEL-28 M13uPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWxNEDPxE1? MYO3NkBp MlrUSG1UVw>? MVnJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hW0tvTVXMMVI5KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPDNizszN NIWzSJQzOzh2NECzPC=>
A375P-F11 NHjCeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXnS|cyOCEQvF2= NIDyXo44OiCq NEPvNodFVVOR NGDz[WtKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iQUO3OXAuTjFzIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yN{Gg{txO MXOyN|g1PDB|OB?=
MALME-3M NVfnbXFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPJZY0yOCEQvF2= NUKydmpOPzJiaB?= MmHqSG1UVw>? M4TxT2lEPTB;MTDuUS=> M2rwb|I{QDR2MEO4
UACC-62 M4fXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHLNVAh|ryP NHXs[m04OiCq NIrBbnVFVVOR MY\JR|UxRTFibl2= MUGyN|g1PDB|OB?=
C32TG M3r1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3vfWZkOTBizszN NYjveml{PzJiaB?= NFjwNJNFVVOR MoXmTWM2OD1zIH7N MlfDNlM5PDRyM{i=
SK-MEL-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr3NVAh|ryP NXzOTo5RPzJiaB?= M3iyWmROW09? NFv5dnFKSzVyPUKgcm0> MmPsNlM5PDRyM{i=
M14 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexNEDPxE1? NHradGM4OiCq NUnLcZJCTE2VTx?= MmfPTWM2OD1{IH7N MXeyN|g1PDB|OB?=
SK-MEL-28 NV7sXHQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmxe3VqOTBizszN NWi4XVBxPzJiaB?= M{PVfWROW09? NGf1cI1KSzVyPUOgcm0> NVjldGpLOjN6NESwN|g>
A375 NYLsOINST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKyW5AyOCEQvF2= Ml;mO|IhcA>? MWPEUXNQ MVjJR|UxRTRibl2= MUGyN|g1PDB|OB?=
DU-4475 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HsT|ExKM7:TR?= MWi3NkBp NW\HTYhoTE2VTx?= M1u1cGlEPTB;NTDuUS=> NX;4V|hkOjN6NESwN|g>
UACC-257 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPkd|JyOTBizszN NFXDVFg4OiCq M3TpbWROW09? NGDPSFlKSzVyPU[gcm0> MYiyN|g1PDB|OB?=
Colo 205 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTKNVAh|ryP M2jIW|czKGh? MmnoSG1UVw>? NWDjbFhTUUN3ME23JI5O MVSyN|g1PDB|OB?=
SK-MEL-3 M2jm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGxNEDPxE1? M{fON|czKGh? M{X5TmROW09? NHXh[IZKSzVyPUegcm0> NHTsSW4zOzh2NECzPC=>
SH-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[wNVAh|ryP M2XwflczKGh? NFrkV5dFVVOR MVfJR|UxRThibl2= NHrDXFkzOzh2NECzPC=>
A101D NUHTXYFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3raTFExKM7:TR?= NXvEPIU5PzJiaB?= M2jUUGROW09? M4DVZ2lEPTB;OTDuUS=> MViyN|g1PDB|OB?=
ES-2 M33ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfqdZd5OTBizszN MknlO|IhcA>? M{TOb2ROW09? NHO0N2tKSzVyPUWzJI5O NXi5Snl5OjN6NESwN|g>
HT-29 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jNRlExKM7:TR?= MUm3NkBp NIfTZYNFVVOR Moe4TWM2OD14NjDuUS=> M3HR[VI{QDR2MEO4
SW1417 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HxXVExKM7:TR?= NYmyXGl2PzJiaB?= MVLEUXNQ M3PrVWlEPTB;MUW4JI5O MYqyN|g1PDB|OB?=
SW872 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K2WFExKM7:TR?= NI\vNGg4OiCq MorRSG1UVw>? NHiydlhKSzVyPUO3O{BvVQ>? M{TUelI{QDR2MEO4
RKO NHPa[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvoXVh3OTBizszN MVe3NkBp M{frc2ROW09? MkGxTWM2OD1{LkWyNkDPxE1? M4PzOVI{QDR2MEO4
A673 NEX3fGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnDSFBDOTBizszN M1joXlczKGh? Mm\YSG1UVw>? MojPTWM2OD1zMDFOwG0> NVzIXG9{OjN6NESwN|g>
GCT NY\zOJJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\t[VExKM7:TR?= NVvMe5lkPzJiaB?= MX;EUXNQ NXXBU4VbUUN3ME2xNEDPxE1? M{XETFI{QDR2MEO4
WM-115 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxNEDPxE1? Ml;TO|IhcA>? NVv2N2RpTE2VTx?= NWK3NldEUUN3ME21JI5O MnriNlM5PDRyM{i=
YUMAC M3SzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzwS4poOTBizszN MW[3NkBp NYm4b4ZMTE2VTx?= M33FWGlEPTB;NTDuUS=> NXm0b3BiOjN6NESwN|g>
OV-90 MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17OTVExKM7:TR?= NWLzUVNrPzJiaB?= NXnFd|cyTE2VTx?= NE\3[5RKSzVyPUK5JI5O MnP4NlM5PDRyM{i=
NCI-H508 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzvXIsyOCEQvF2= NIHOUo04OiCq NHXkOIxFVVOR MnPWTWM2OD1zMDFOwG0> M2j0b|I{QDR2MEO4
MDA-MB-231 M{LXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7yVGxiOTBizszN NIDUSWQ4OiCq MmTJSG1UVw>? NVuxdoQ1UUN3ME2xNEDPxE1? NV\aWWZEOjN6NESwN|g>
SW756 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfWNVAh|ryP NYnWVm9rPzJiaB?= NHzPcphFVVOR NHi2fHpKSzVyPUGwJO69VQ>? MWCyN|g1PDB|OB?=
SW-837 NVTRNpd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLxRZRtOTBizszN MVq3NkBp MkTsSG1UVw>? NX3zTnltUUN3ME2xNEDPxE1? M3\NNVI{QDR2MEO4
UMUC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7EVVUyOCEQvF2= MXm3NkBp MUjEUXNQ NFPL[ZZKSzVyPUGwJO69VQ>? NXvkS4xnOjN6NESwN|g>
LS-174T M2rxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[xNEDPxE1? NH\2VGY4OiCq NYXteJpSTE2VTx?= M1mxXmlEPTB;MUCg{txO NGjrUIMzOzh2NECzPC=>
A549 Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWxNEDPxE1? NVnyWpJ1PzJiaB?= M{nodmROW09? Mm\HTWM2OD1zMDFOwG0> MUmyN|g1PDB|OB?=
SHP-77 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O0UlExKM7:TR?= NWTLUY5tPzJiaB?= MWHEUXNQ MkXsTWM2OD1zMDFOwG0> NYP6b244OjN6NESwN|g>
SW480 MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXLOIk4OTBizszN NYLqN2NsPzJiaB?= Mo\USG1UVw>? MYXJR|UxRTFyIN88US=> M2TlZ|I{QDR2MEO4
DLD-1 NG\1WG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOwfGUyOCEQvF2= NWrt[YtYPzJiaB?= Mln5SG1UVw>? NYXxOXp1UUN3ME2xNEDPxE1? M3PqR|I{QDR2MEO4
HCT-116 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofXNVAh|ryP MmXDO|IhcA>? Mlv0SG1UVw>? MkS3TWM2OD1zMDFOwG0> MlHhNlM5PDRyM{i=
NCI-H747 M1ztfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P1clExKM7:TR?= MXK3NkBp Ml;NSG1UVw>? M3vYd2lEPTB;MUCg{txO NH20c2EzOzh2NECzPC=>
T-84 M2\WeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYixNEDPxE1? Ml3ZO|IhcA>? NV3RW3ZFTE2VTx?= MYrJR|UxRTFyIN88US=> M1vlcVI{QDR2MEO4
NCI-H460 M{HO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYexNEDPxE1? NGezNZg4OiCq MkK3SG1UVw>? Mly4TWM2OD1zMDFOwG0> NVjDW45LOjN6NESwN|g>
Calu-6 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j2VlExKM7:TR?= M{XCW|czKGh? Mn7jSG1UVw>? M3u0[mlEPTB;MUCg{txO MYmyN|g1PDB|OB?=
HCC-2998 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljzNVAh|ryP M4HPelczKGh? Mn;wSG1UVw>? Ml\hTWM2OD1zMDFOwG0> NIXqOYEzOzh2NECzPC=>
LS1034 NWTzRWN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TtNFExKM7:TR?= MljNO|IhcA>? M1eyd2ROW09? MmC2TWM2OD1zMDFOwG0> MYmyN|g1PDB|OB?=
CHP-212 NUf1XXd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TXbVExKM7:TR?= MnLUO|IhcA>? MlTiSG1UVw>? NH;DSFhKSzVyPUGwJO69VQ>? MYKyN|g1PDB|OB?=
SK-N-AS MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvFNVAh|ryP M4qybFczKGh? MoDLSG1UVw>? NEnmTm1KSzVyPUGwJO69VQ>? NWrIRWxROjN6NESwN|g>
BFTC-905 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W2RlExKM7:TR?= MUm3NkBp NGrzUG1FVVOR NUGyU3ZMUUN3ME2xNEDPxE1? NVXFdXpkOjN6NESwN|g>
HuT78 NFfmXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;sTlEyOCEQvF2= NVz3eG9RPzJiaB?= M2XqemROW09? Mn3MTWM2OD13MjDuUS=> MVmyN|g1PDB|OB?=
RPMI-8226 NGX6VHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\MNVAh|ryP MonMO|IhcA>? MWjEUXNQ MUDJR|UxRTJ4MzDuUS=> Ml60NlM5PDRyM{i=
BC-3 NUDpZ3NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX2NVAh|ryP M{Dwb|czKGh? MkDXSG1UVw>? NFvpc|VKSzVyPUK3O{BvVQ>? NETVbHczOzh2NECzPC=>
ACHN MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M174cVExKM7:TR?= MlTUO|IhcA>? NEnsdJpFVVOR NXu0OW1lUUN3ME2yPVQhdk1? NX\ubJpWOjN6NESwN|g>
JRT3-T35 NFPvZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jQfFExKM7:TR?= MV[3NkBp MlP6SG1UVw>? M3e0eGlEPTB;Mkm1JI5O M2r0R|I{QDR2MEO4
SK-MES-1 NIOzWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKzNVAh|ryP MoPSO|IhcA>? M1PQdWROW09? NHXsdZhKSzVyPUOyPUBvVQ>? NX3UcJJ1OjN6NESwN|g>
CESS NGfVb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPCS|NDOTBizszN MUS3NkBp MXfEUXNQ Ml3XTWM2OD12OUegcm0> MmezNlM5PDRyM{i=
H4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjTNVAh|ryP MoPnO|IhcA>? M4S2U2ROW09? NEnVTIlKSzVyPU[xPUBvVQ>? M4f2Z|I{QDR2MEO4
BC-1 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLvcmVKOTBizszN MXy3NkBp Mn33SG1UVw>? M1zXO2lEPTB;N{C0JI5O MmnDNlM5PDRyM{i=
DB MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPoNIg3OTBizszN NGjMXnQ4OiCq NUPwSmpJTE2VTx?= MoC5TWM2OD16N{Ogcm0> NEPKeWgzOzh2NECzPC=>
RPMI-6666 NWC3VGJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT2NVAh|ryP NHzwS5k4OiCq NXHRSHpVTE2VTx?= NFPWRlRKSzVyPUmyPEBvVQ>? NHXD[ZEzOzh2NECzPC=>
MC/CAR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTWNVAh|ryP MkW4O|IhcA>? M{PTNGROW09? NVrLfYNyUUN3ME2xMlAxOiEQvF2= MWmyN|g1PDB|OB?=
SNU-1 NFPxdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ZXW5JOTBizszN MXy3NkBp M4PFZWROW09? NWriWIdSUUN3ME2xMlUxOSEQvF2= M{TWc|I{QDR2MEO4
CEM/C1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nt[lExKM7:TR?= MnPuO|IhcA>? MYjEUXNQ M4TDdGlEPTB;MT63O|Mh|ryP MXeyN|g1PDB|OB?=
GDM-1 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILDXWYyOCEQvF2= M4qyVFczKGh? MWTEUXNQ M2L0UmlEPTB;MT65PVch|ryP M{PBb|I{QDR2MEO4
HT-1080 NVPDNY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf3NVAh|ryP MUi3NkBp NHHsR3lFVVOR MkDCTWM2OD1{LkCwOEDPxE1? NGWwVmgzOzh2NECzPC=>
HL-60 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T2OVExKM7:TR?= MlnDO|IhcA>? M3\TVWROW09? M3HNZWlEPTB;Mj6xO|gh|ryP M{OyeFI{QDR2MEO4
C3A MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfaRlkyOCEQvF2= M1\BOVczKGh? MV3EUXNQ NHq1clJKSzVyPUWuOFE1KM7:TR?= MViyN|g1PDB|OB?=
MES-SA M3nZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXmeFUyOCEQvF2= NIHsbJo4OiCq M3rPd2ROW09? NXi0UlF{UUN3ME22Mlk5QSEQvF2= MWOyN|g1PDB|OB?=
22Rv1 NW\NN5IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqxNEDPxE1? MnjBO|IhcA>? MYjEUXNQ NXXYW3ZJUUN3ME2xNEDPxE1? NVraTlhFOjN6NESwN|g>
647-V M{D5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLSWGcyOCEQvF2= NXX5cYNLPzJiaB?= NEDLRpVFVVOR NHPTOopKSzVyPUGwJO69VQ>? NVTIfGpKOjN6NESwN|g>
786-O NXHQZoJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z3[VExKM7:TR?= MmK4O|IhcA>? MlvISG1UVw>? M4fSZ2lEPTB;MUCg{txO NFH5RVEzOzh2NECzPC=>
A172 M3LISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[0fVMxOTBizszN NH7QRng4OiCq M{G1fGROW09? MWrJR|UxRTFyIN88US=> MUWyN|g1PDB|OB?=
A204 NGHDZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33SXVExKM7:TR?= MXm3NkBp M1rFemROW09? MV;JR|UxRTFyIN88US=> MX6yN|g1PDB|OB?=
A427 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCxNEDPxE1? M1jHbVczKGh? NGrIR2JFVVOR M3TOfGlEPTB;MUCg{txO MV[yN|g1PDB|OB?=
A431 NGLBeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX6NVAh|ryP NH;xRZM4OiCq Mm\TSG1UVw>? NIPkS21KSzVyPUGwJO69VQ>? NFzIWIEzOzh2NECzPC=>
A2780 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vtRVExKM7:TR?= NWC3XmRkPzJiaB?= NYPwPVZvTE2VTx?= MojrTWM2OD1zMDFOwG0> M1PkRVI{QDR2MEO4
ARH-77 M163NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXJT2NMOTBizszN MUC3NkBp MkHtSG1UVw>? NEnp[IZKSzVyPUGwJO69VQ>? MWKyN|g1PDB|OB?=
Be(2)C MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzuc4wyOCEQvF2= NWrGNVhzPzJiaB?= M1TUNGROW09? NELicJpKSzVyPUGwJO69VQ>? M1fGd|I{QDR2MEO4
BT-20 NUmwR4dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNEDPxE1? Mm\RO|IhcA>? Mm\LSG1UVw>? NXixNlFrUUN3ME2xNEDPxE1? NXfMTXk4OjN6NESwN|g>
BxPc3 Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzmNVAh|ryP MWG3NkBp NW\3Xod7TE2VTx?= NYTQeVBbUUN3ME2xNEDPxE1? MVKyN|g1PDB|OB?=
C-4 I NXvVeZN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fuflExKM7:TR?= MYm3NkBp NGewPIhFVVOR NGLsPG9KSzVyPUGwJO69VQ>? NHvBenozOzh2NECzPC=>
C33A MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml6yNVAh|ryP M{TqcFczKGh? MlXnSG1UVw>? NHjXV2dKSzVyPUGwJO69VQ>? M3[0clI{QDR2MEO4
CAL-27 NVSwR255T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzaNVAh|ryP M3zON|czKGh? NFL6VIlFVVOR M1TZWGlEPTB;MUCg{txO MUOyN|g1PDB|OB?=
CAL-62 NXO0N5FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[xNEDPxE1? MVu3NkBp NGnZPHZFVVOR MmnzTWM2OD1zMDFOwG0> MlPSNlM5PDRyM{i=
Calu-3 NXHGcpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfGcWZIOTBizszN MXi3NkBp NV7icGlvTE2VTx?= MYXJR|UxRTFyIN88US=> NEjUVGwzOzh2NECzPC=>
CaOV3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPwNVAh|ryP M3S5[lczKGh? MXXEUXNQ MmrFTWM2OD1zMDFOwG0> M2DU[lI{QDR2MEO4
CGTHW1 NGTNcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSxNEDPxE1? M4nQe|czKGh? NH:zWnJFVVOR NUfqWodbUUN3ME2xNEDPxE1? MUeyN|g1PDB|OB?=
CHL-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX2NVAh|ryP NUf5TZhwPzJiaB?= MYnEUXNQ MULJR|UxRTFyIN88US=> M2rscVI{QDR2MEO4
Colo320DM NE\LO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfoUlkyOCEQvF2= MkDtO|IhcA>? MkfKSG1UVw>? NVXyeZpKUUN3ME2xNEDPxE1? NW\WU2VUOjN6NESwN|g>
Colo704 NFPBPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq2TodQOTBizszN M1vqSlczKGh? NGXmeodFVVOR NYPwZXVTUUN3ME2xNEDPxE1? MU[yN|g1PDB|OB?=
COR-L23 NGLIR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TENVExKM7:TR?= MmfSO|IhcA>? NWX3enRHTE2VTx?= M{nrc2lEPTB;MUCg{txO NFPPUGczOzh2NECzPC=>
CRO-AP2 NH2yT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L5VFExKM7:TR?= Mmi2O|IhcA>? NFzLVmRFVVOR NFKyUG1KSzVyPUGwJO69VQ>? NVX1PY5COjN6NESwN|g>
Daudi MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqxNEDPxE1? NYfwN2pzPzJiaB?= MmG1SG1UVw>? MVjJR|UxRTFyIN88US=> NHLNeYYzOzh2NECzPC=>
DOTC 24510 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr4NVAh|ryP M3T0PVczKGh? MX;EUXNQ NHLnSoNKSzVyPUGwJO69VQ>? NGrvVHozOzh2NECzPC=>
DU-145 M1jFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n1Z|ExKM7:TR?= NISw[Gs4OiCq NFfLZXdFVVOR NV2we5ZrUUN3ME2xNEDPxE1? M{C1PFI{QDR2MEO4
EB-3 NV;iUZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILPV2QyOCEQvF2= NH3tTWo4OiCq MYfEUXNQ NYHlTopXUUN3ME2xNEDPxE1? M3LueVI{QDR2MEO4
EFM-19 NEPkO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLrNVAh|ryP NXLte3ZkPzJiaB?= NEThfFVFVVOR NWe1bXBHUUN3ME2xNEDPxE1? NWSzfZF1OjN6NESwN|g>
EKVX M4f1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD4XHkyOCEQvF2= NYHZUGxXPzJiaB?= NFTj[3JFVVOR NVLZO3dNUUN3ME2xNEDPxE1? MX2yN|g1PDB|OB?=
FaDu NFz3V2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxNEDPxE1? M3HEZVczKGh? NWn0NoZ5TE2VTx?= NUfXZZdNUUN3ME2xNEDPxE1? NYK0d2h3OjN6NESwN|g>
G401 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjxTnFDOTBizszN NG\RVFA4OiCq Mm\qSG1UVw>? MYTJR|UxRTFyIN88US=> NFTzR3UzOzh2NECzPC=>
HCC-70 NVrlV5BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVixNEDPxE1? MV[3NkBp MX;EUXNQ MnPQTWM2OD1zMDFOwG0> M2GwZ|I{QDR2MEO4
HCC-1954 M3jZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TuZ|ExKM7:TR?= MV[3NkBp NH;PV5dFVVOR MoryTWM2OD1zMDFOwG0> NUjwNWNCOjN6NESwN|g>
Hela MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexNEDPxE1? M2X5PVczKGh? MkL5SG1UVw>? MVXJR|UxRTFyIN88US=> NYPjSFhVOjN6NESwN|g>
Hep3B NVTtWIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i4blExKM7:TR?= NFHaWms4OiCq M3;yemROW09? M1L3bWlEPTB;MUCg{txO NE\veFYzOzh2NECzPC=>
HMCB M2HxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[xNEDPxE1? NV:5NZhwPzJiaB?= M1PYVWROW09? MXfJR|UxRTFyIN88US=> MVWyN|g1PDB|OB?=
HN5 NGPxSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSxNEDPxE1? MYq3NkBp NWnjenN4TE2VTx?= NHjDcJJKSzVyPUGwJO69VQ>? MmC4NlM5PDRyM{i=
HOS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[xNEDPxE1? MUO3NkBp M1zGWGROW09? M{HJOGlEPTB;MUCg{txO MnjpNlM5PDRyM{i=
HPAF-II NHrs[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHThfZcyOCEQvF2= MorTO|IhcA>? NGP1V2JFVVOR M1X6TGlEPTB;MUCg{txO NVWzfHJjOjN6NESwN|g>
Hs746.T NIXZb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13xeVExKM7:TR?= NHrt[2E4OiCq NULzbocyTE2VTx?= NWHuS4N3UUN3ME2xNEDPxE1? NWDUeFQ{OjN6NESwN|g>
HT NWnSZ4dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;SNVAh|ryP M2TIZVczKGh? MmDSSG1UVw>? NIjzR5pKSzVyPUGwJO69VQ>? NFXnOlUzOzh2NECzPC=>
HT-3 M2TFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTSNVAh|ryP M4fWSlczKGh? NGjKT4hFVVOR NEnSPJNKSzVyPUGwJO69VQ>? NFWxdmczOzh2NECzPC=>
HuNS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnoRlJFOTBizszN MVq3NkBp M4X4UmROW09? MVvJR|UxRTFyIN88US=> MWKyN|g1PDB|OB?=
IGROV1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPTPIcyOCEQvF2= MXu3NkBp MWjEUXNQ MUTJR|UxRTFyIN88US=> M1jHN|I{QDR2MEO4
J82 M4fs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWxNEDPxE1? NED5RYw4OiCq NHLvWGVFVVOR MXHJR|UxRTFyIN88US=> M4XnSVI{QDR2MEO4
JM1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoniNVAh|ryP MXi3NkBp Ml;iSG1UVw>? NXvhRpk1UUN3ME2xNEDPxE1? NUH4fFRWOjN6NESwN|g>
Kato III NFrFelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjoS44yOCEQvF2= MnXlO|IhcA>? MY\EUXNQ NFXifllKSzVyPUGwJO69VQ>? NIrMb48zOzh2NECzPC=>
KHOS-240S NFeyVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILDUlYyOCEQvF2= MVS3NkBp MVnEUXNQ MlT5TWM2OD1zMDFOwG0> M3PEcVI{QDR2MEO4
KM-12 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WwSlExKM7:TR?= M1;UNVczKGh? MVPEUXNQ MVXJR|UxRTFyIN88US=> Mn6zNlM5PDRyM{i=
KPL-1 M2D1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSxcYVvOTBizszN MnzqO|IhcA>? M3fic2ROW09? NXfNc3pvUUN3ME2xNEDPxE1? M4DDXFI{QDR2MEO4
KYSE-30 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrlNVAh|ryP M2rNTVczKGh? NUL3VFdTTE2VTx?= M4W3SmlEPTB;MUCg{txO MoPrNlM5PDRyM{i=
LNCaP NYrLTnBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;3RodbOTBizszN NY\J[Jo{PzJiaB?= NHPOcXBFVVOR MmPGTWM2OD1zMDFOwG0> NW\sVYVnOjN6NESwN|g>
MCF-7 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\tOmkyOCEQvF2= MV:3NkBp M3LwOmROW09? NXnDblVpUUN3ME2xNEDPxE1? M2TLO|I{QDR2MEO4
MC-IXC M1XjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fUfVExKM7:TR?= Mle2O|IhcA>? MYPEUXNQ NYPLdmlTUUN3ME2xNEDPxE1? M2\sbVI{QDR2MEO4
MDA-MB-175 VII NEfBXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7zcWYyOCEQvF2= M2G0NFczKGh? NGPHPZNFVVOR M{ThdGlEPTB;MUCg{txO NIWwfogzOzh2NECzPC=>
MDA-MB-468 NEPROFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPYNVAh|ryP NFKzXWc4OiCq MYLEUXNQ NF\6d5ZKSzVyPUGwJO69VQ>? MmTvNlM5PDRyM{i=
MiaPaCa NECz[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxNEDPxE1? NHHUWFM4OiCq NEnyUZFFVVOR NX3tUnpOUUN3ME2xNEDPxE1? M2nZTFI{QDR2MEO4
Molt-4 NHqyUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO0NVAh|ryP NUDJ[2h5PzJiaB?= NVjGU4hITE2VTx?= MoXjTWM2OD1zMDFOwG0> NGLy[mczOzh2NECzPC=>
NCI-ADR/RES MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;ybWFFOTBizszN MVO3NkBp MUHEUXNQ NWLFe5JLUUN3ME2xNEDPxE1? NHm0U5EzOzh2NECzPC=>
NCI-H69 M2rvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm2c|YyOCEQvF2= NUHV[25iPzJiaB?= MW\EUXNQ NFvC[VRKSzVyPUGwJO69VQ>? MXOyN|g1PDB|OB?=
NCI-H82 M1\nNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j6V|ExKM7:TR?= NIHpUGk4OiCq NX;vcWJVTE2VTx?= NGjGS3RKSzVyPUGwJO69VQ>? M4eyTFI{QDR2MEO4
NCI-N87 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfVNVAh|ryP M2TwZlczKGh? MYfEUXNQ MnflTWM2OD1zMDFOwG0> MYCyN|g1PDB|OB?=
NCI-H146 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[xNEDPxE1? NUPQSmQ4PzJiaB?= M4\MRWROW09? NGq5cJNKSzVyPUGwJO69VQ>? NVG0bmtuOjN6NESwN|g>
NCI-H157 NFfDU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7TXIMyOCEQvF2= MmnXO|IhcA>? NHvlelRFVVOR M375UGlEPTB;MUCg{txO NHm0WYMzOzh2NECzPC=>
NCI-H187 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XDb|ExKM7:TR?= M{SyZlczKGh? MlzDSG1UVw>? M1W1dGlEPTB;MUCg{txO MmLVNlM5PDRyM{i=
NCI-H209 MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEWxUlgyOCEQvF2= MoTtO|IhcA>? MWHEUXNQ MUDJR|UxRTFyIN88US=> MlrFNlM5PDRyM{i=
NCI-H226 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoroNVAh|ryP NY\Nd445PzJiaB?= M33HSWROW09? MX;JR|UxRTFyIN88US=> NXm3[FdlOjN6NESwN|g>
NCI-H292 NFnlVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13IPFExKM7:TR?= NInnOVE4OiCq M2LVdGROW09? M2LQOWlEPTB;MUCg{txO NYnubmJ6OjN6NESwN|g>
NCI-H322 MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXhNVAh|ryP M2nPeVczKGh? MnzUSG1UVw>? NF\SUHlKSzVyPUGwJO69VQ>? NIThNFMzOzh2NECzPC=>
NCI-H358 NWPkSnVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNEDPxE1? MXm3NkBp M1PYU2ROW09? NG\XS3dKSzVyPUGwJO69VQ>? NYe3S4tDOjN6NESwN|g>
NCI-H520 NHKxTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLw[4FKOTBizszN MWO3NkBp MkWwSG1UVw>? NGfKbmlKSzVyPUGwJO69VQ>? MVWyN|g1PDB|OB?=
NCI-H526 NXrSS3pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;WS3lsOTBizszN MorJO|IhcA>? NUPSOnAzTE2VTx?= MXLJR|UxRTFyIN88US=> MmXaNlM5PDRyM{i=
NCI-H630 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuxNEDPxE1? Mm[0O|IhcA>? NEfCSXlFVVOR M2\URWlEPTB;MUCg{txO M{LNe|I{QDR2MEO4
NCI-H661 MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGxNEDPxE1? NVjUeY11PzJiaB?= MXLEUXNQ NVLjXYh{UUN3ME2xNEDPxE1? NEXnV4UzOzh2NECzPC=>
NCI-H716 M171e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHFO3YyOCEQvF2= M1rDb|czKGh? NYTNVohyTE2VTx?= MoDaTWM2OD1zMDFOwG0> MXmyN|g1PDB|OB?=
NCI-H1563 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjSNVAh|ryP NXXYV4JvPzJiaB?= MXjEUXNQ NHfkWoNKSzVyPUGwJO69VQ>? MVyyN|g1PDB|OB?=
NCI-H1792 M4fpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTxenUzOTBizszN Mof0O|IhcA>? M2jub2ROW09? MU\JR|UxRTFyIN88US=> NXjTOmFVOjN6NESwN|g>
NCI-H2030 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvzNVAh|ryP NWDRS49{PzJiaB?= M4P1fmROW09? MWfJR|UxRTFyIN88US=> MlPTNlM5PDRyM{i=
NCI-H2052 NUfNZWJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVexNEDPxE1? NW[wSmVRPzJiaB?= NFLHW5VFVVOR NYDEU5BMUUN3ME2xNEDPxE1? MXiyN|g1PDB|OB?=
NCI-H2122 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XkbFExKM7:TR?= Mn7QO|IhcA>? NHXLbVhFVVOR MV3JR|UxRTFyIN88US=> Mm\WNlM5PDRyM{i=
NCI-H2228 NX3ofXdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rYTlExKM7:TR?= NYr1N5J3PzJiaB?= M2rMWmROW09? MXfJR|UxRTFyIN88US=> NHzG[HYzOzh2NECzPC=>
OE-19 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nFNlExKM7:TR?= NHK4V3c4OiCq M2WwZ2ROW09? NXjlRmxxUUN3ME2xNEDPxE1? NF;UWmczOzh2NECzPC=>
OE-21 NH;3eFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f0TFExKM7:TR?= NVfyNlRpPzJiaB?= NIrheHVFVVOR NGHoUHdKSzVyPUGwJO69VQ>? NGjTboEzOzh2NECzPC=>
OE-33 NGC5Z5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGxNEDPxE1? NFPjWHY4OiCq M2LaZmROW09? MkDQTWM2OD1zMDFOwG0> M2HVe|I{QDR2MEO4
OVCAR-3 NV;JNpdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKwNVAh|ryP M{fZR|czKGh? Moj6SG1UVw>? MlHoTWM2OD1zMDFOwG0> MXqyN|g1PDB|OB?=
OVCAR-4 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHSRW1kOTBizszN NX;vSYY{PzJiaB?= MlLaSG1UVw>? MUXJR|UxRTFyIN88US=> MUeyN|g1PDB|OB?=
OVCAR-5 NIDEbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\QNVAh|ryP NYDFR2F6PzJiaB?= MVXEUXNQ Mn;0TWM2OD1zMDFOwG0> M2LCN|I{QDR2MEO4
P3HR-1 M2LXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon4NVAh|ryP MlzkO|IhcA>? MY\EUXNQ MWPJR|UxRTFyIN88US=> NV7pOW5rOjN6NESwN|g>
PC-3 M{PCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP2NVAh|ryP Mn7rO|IhcA>? NXHjfZFuTE2VTx?= NGPt[W1KSzVyPUGwJO69VQ>? MUGyN|g1PDB|OB?=
Raji Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL5NVAh|ryP M4f2VFczKGh? NX;D[FliTE2VTx?= MW\JR|UxRTFyIN88US=> NES0ZZkzOzh2NECzPC=>
RD MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjTNVAh|ryP NXzWSIJGPzJiaB?= NFSySoFFVVOR MX\JR|UxRTFyIN88US=> NHzSTXEzOzh2NECzPC=>
RD-ES NHnu[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKzXWgyOCEQvF2= M3v4[lczKGh? MY\EUXNQ M2HOc2lEPTB;MUCg{txO NF\zeGgzOzh2NECzPC=>
RL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOxNEDPxE1? MlvYO|IhcA>? MlXUSG1UVw>? MXXJR|UxRTFyIN88US=> MmTtNlM5PDRyM{i=
SaOS2 M4PR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO0NVB7OTBizszN M2PUS|czKGh? NInNWZlFVVOR NHzjWFJKSzVyPUGwJO69VQ>? NFnvdo0zOzh2NECzPC=>
SCC-9 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfkNVAh|ryP NGTrT2U4OiCq MY\EUXNQ M1\aSGlEPTB;MUCg{txO Mn\NNlM5PDRyM{i=
SCC-12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxNEDPxE1? MlvwO|IhcA>? NUWxXItbTE2VTx?= MVjJR|UxRTFyIN88US=> MX6yN|g1PDB|OB?=
SCC-13 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:xNEDPxE1? NUXqbXZKPzJiaB?= MmXDSG1UVw>? M3fZdmlEPTB;MUCg{txO Moj3NlM5PDRyM{i=
SCC-15 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnUPHYyOTBizszN M1OySFczKGh? NFv5PVRFVVOR MkDYTWM2OD1zMDFOwG0> NF7wSJgzOzh2NECzPC=>
SCC-25 MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTkb5BGOTBizszN NV\Nc5hwPzJiaB?= MnGwSG1UVw>? NF33coxKSzVyPUGwJO69VQ>? NWXmU21TOjN6NESwN|g>
SCLC-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLLO3VLOTBizszN NVi0e3FOPzJiaB?= NEXBUnNFVVOR NF;m[WlKSzVyPUGwJO69VQ>? MmrzNlM5PDRyM{i=
SF-268 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKxNEDPxE1? MWe3NkBp M2TUcmROW09? M1nKdGlEPTB;MUCg{txO MUeyN|g1PDB|OB?=
SF-295 NX:2T5puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWxNEDPxE1? NF3Wc|Q4OiCq NEL1O4xFVVOR MmG3TWM2OD1zMDFOwG0> M4mzZ|I{QDR2MEO4
SJRH30 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWxNEDPxE1? M3\wRVczKGh? Mm\qSG1UVw>? MlzCTWM2OD1zMDFOwG0> NV;sbnBOOjN6NESwN|g>
SK-BR-3 M{[xUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjifWQxOTBizszN MmKyO|IhcA>? NVvtPXBKTE2VTx?= MnvBTWM2OD1zMDFOwG0> NEjwRVIzOzh2NECzPC=>
SK-LMS-1 NFjZXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWeybHZHOTBizszN MkjQO|IhcA>? MWnEUXNQ MVzJR|UxRTFyIN88US=> MorTNlM5PDRyM{i=
SK-N-DZ MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjkR2QyOCEQvF2= M1zreFczKGh? M1;jXWROW09? NIrXcYhKSzVyPUGwJO69VQ>? NFOwRnMzOzh2NECzPC=>
SK-N-F1 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K4N|ExKM7:TR?= MUi3NkBp NV3WcGVnTE2VTx?= NVHmdJp5UUN3ME2xNEDPxE1? MlnvNlM5PDRyM{i=
SKOV-3 M3rCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PNTlExKM7:TR?= NFXoTWY4OiCq NGnKbVNFVVOR NVT3OnVRUUN3ME2xNEDPxE1? MlzWNlM5PDRyM{i=
SK-UT-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfZfIkyOCEQvF2= M1K2UVczKGh? NIPISGJFVVOR MlHiTWM2OD1zMDFOwG0> M{PvRlI{QDR2MEO4
SN12C NGLiVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPuOZJkOTBizszN NYnWRYRjPzJiaB?= M4TXc2ROW09? MlnSTWM2OD1zMDFOwG0> MoDLNlM5PDRyM{i=
SNB-19 M4LSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnRNVAh|ryP NYLXRnQ4PzJiaB?= NG\pNJZFVVOR NFT3TYlKSzVyPUGwJO69VQ>? M4GyblI{QDR2MEO4
SNU-5 NH\CPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm3NVAh|ryP Mki5O|IhcA>? M4fhO2ROW09? M3fsfGlEPTB;MUCg{txO NXvwSG5yOjN6NESwN|g>
SNU-16 NEOxSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPkflMyOCEQvF2= MX[3NkBp MkfkSG1UVw>? M2TNfmlEPTB;MUCg{txO NVvLVZBrOjN6NESwN|g>
SNU-398 NHPnfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{GyTFExKM7:TR?= MUW3NkBp MlvTSG1UVw>? NWPFfJpjUUN3ME2xNEDPxE1? MXyyN|g1PDB|OB?=
SNU-449 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnIeGEyOCEQvF2= MkDDO|IhcA>? MkjsSG1UVw>? Mk\WTWM2OD1zMDFOwG0> MVSyN|g1PDB|OB?=
SR MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDlNVAh|ryP MXy3NkBp NHrEWopFVVOR NHjzS|JKSzVyPUGwJO69VQ>? NULCdJJ5OjN6NESwN|g>
ST486 M3LIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrGNVAh|ryP MlPlO|IhcA>? NV:zU4ZvTE2VTx?= NY\COnlMUUN3ME2xNEDPxE1? NIHneIUzOzh2NECzPC=>
SW579 MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\MOXYyOCEQvF2= MV[3NkBp MXXEUXNQ NYK4XmJ5UUN3ME2xNEDPxE1? Mn;hNlM5PDRyM{i=
SW684 NVKyOW12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;5NHAyOCEQvF2= MonhO|IhcA>? NFjwe|FFVVOR M1PWO2lEPTB;MUCg{txO NGXuR3EzOzh2NECzPC=>
SW-780 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zuW|ExKM7:TR?= M2Lh[VczKGh? M3jCU2ROW09? MVPJR|UxRTFyIN88US=> NIrKWVMzOzh2NECzPC=>
SW900 M1[1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrVRWNsOTBizszN Ml70O|IhcA>? MoXySG1UVw>? MXjJR|UxRTFyIN88US=> MlnDNlM5PDRyM{i=
SW1088 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfGN4IyOCEQvF2= MmXyO|IhcA>? NULJbYJxTE2VTx?= MUXJR|UxRTFyIN88US=> M4L3XlI{QDR2MEO4
SW1463 NH\0dlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP3[oYyOCEQvF2= NXXVU|l3PzJiaB?= M1THZ2ROW09? MoTCTWM2OD1zMDFOwG0> MVOyN|g1PDB|OB?=
SW1990 M2DVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNEDPxE1? MWG3NkBp NXvpWXhFTE2VTx?= MX3JR|UxRTFyIN88US=> NU\mOlNUOjN6NESwN|g>
T47D M{XjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[xNEDPxE1? MkPZO|IhcA>? NHP0d3NFVVOR NYrCNYxHUUN3ME2xNEDPxE1? NFL2UGUzOzh2NECzPC=>
TE381.T NUfLc2I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK4NVAh|ryP M{DpRVczKGh? MUHEUXNQ NG\X[XpKSzVyPUGwJO69VQ>? NELSTnEzOzh2NECzPC=>
TK-10 NVrnN4RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNEDPxE1? Mn3uO|IhcA>? MUPEUXNQ MWLJR|UxRTFyIN88US=> MV6yN|g1PDB|OB?=
U2OS M1z0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r2SVExKM7:TR?= Mn;JO|IhcA>? Mk\CSG1UVw>? MVzJR|UxRTFyIN88US=> MmjnNlM5PDRyM{i=
U251 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1mzb|ExKM7:TR?= NGfGenA4OiCq M{HoW2ROW09? M3LLNGlEPTB;MUCg{txO MUKyN|g1PDB|OB?=
UACC-812 NYPmcYZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVWxNEDPxE1? MXy3NkBp M1G3cWROW09? MoS0TWM2OD1zMDFOwG0> MlHSNlM5PDRyM{i=
YAPC NGL4V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojYNVAh|ryP MVy3NkBp MlfHSG1UVw>? M{C1OmlEPTB;MUCg{txO MWqyN|g1PDB|OB?=
ZR-75-1 NFH4SnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vJXVExKM7:TR?= M4rhR|czKGh? M1v0[2ROW09? Mnm1TWM2OD1zMDFOwG0> NYTYUVF7OjN6NESwN|g>
A375 M3HZcWZ2dmO2aX;uJIF{e2G7 NITaN20yNjJizszN NWPaenJYPCCq M17FZmROW09? NXm0N3NYUW6qaXLpeIlwdiCxZjDwbI9{eGixconsZZRqd25ib3[gUWVMNCCHUlusJIFv\CCVNmC= NHjrVoYzOjN6OUS3NS=>
YUSIT1 Mmr1SpVv[3Srb36gZZN{[Xl? MonjSG1UVw>? NHjXWWNz\WS3Y3XkJJNmdnOrdHn2bZR6KHerdHigTWM2OCB-IECuOUDPxE1? NEfkVHMzOjN6OUS3NS=>
MeWo MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MULEUXNQ MoXxTWM2OCB;IEm4O{BvVQ>? MVyyOlAyQDV{NB?=
WiDr MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mk\KSG1UVw>? NHj4cGZKSzVyIE2gO|Yhdk1? MYGyOlAyQDV{NB?=
Colo-205 NX\1cIpUTnWwY4Tpc44h[XO|YYm= M2HFb|Eh|ryP M{P0UlQh\A>? MnTmSG1UVw>? Mke1TY5lfWOnZDDhJIhq\2iueTDjc41x[XKjYnzlJINwdXCjY4Tpc44heGinbn;0fZBm NUP3SXNFOjV|OEGxOVI>
RBW-1 Mof6SpVv[3Srb36gZZN{[Xl? NXr0OHdCOSEQvF2= MUTEUXNQ MXvOc{Bz\WS3Y4Tpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> NFfsfVkzPDh6NU[5NC=>
RBO-1 NFXQVHJHfW6ldHnvckBie3OjeR?= MWGxJO69VQ>? Mmj3SG1UVw>? MmDFTY5pcWKrdHnvckBw\iCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=> MYqyOFg5PTZ7MB?=
RBO-2 NYfOWJN1TnWwY4Tpc44h[XO|YYm= NG\5UW4yKM7:TR?= M3fMNmROW09? NUH1b4tRUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25? NW[0UZlXOjR6OEW2PVA>
RBOW NXjPXFZ5TnWwY4Tpc44h[XO|YYm= NX:4O3pSOSEQvF2= MlPESG1UVw>? M4XobWlvcGmkaYTpc44hd2ZiIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v NYHVTW9WOjR6OEW2PVA>
M257 NVrMXmM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[xNFAhdk1? MWS3NkBp Ml\2SI9meyCwb4SgbY5pcWKrdDDwdo9tcW[ncnH0bY9vKG:oIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGI MV:yN|MyPzR2Nh?=
LCP NHL5PZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fUSFExOCCwTR?= NHi3Soo4OiCq MmDqTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKEyFUDDj[YxtKGijcnLveZJqdmdiQmLBSkBXPjByUjDteZRidnSjdHnvci=> MoO1NlM{OTd2NE[=
WM266 M2joZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;FVXlsOTByIH7N NH\1VWE4OiCq M1L4V2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCZTUK2OkBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCxSEBufXSjboTheIlwdg>? NXXtOIxQOjN|MUe0OFY>
M257 NXfVTJZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnGNVAxKG6P NV3BSGJCPzJiaB?= MYfEc4V{KG6xdDDpcohq[mm2IFXST|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTUK1O{Bk\WyuIHjhdoJwfXKrbnege4lt\CC2eYDlJGJTSUZ? M3uyc|I{OzF5NES2
LCP M{LaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ENVAxKG6P M{\L[FczKGh? M2eyZ2lvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDMR3Ah[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNHIhdXW2YX70ZZRqd25? MVSyN|MyPzR2Nh?=
WM266 Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;5NVAxKG6P NF:xbVg4OiCq MoHtTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBFKG23dHHueIF1cW:w M4[2VVI{OzF5NES2

... Click to View More Cell Line Experimental Data

In vivo Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 519.56
Formula

C23H20F3N5O2S2

CAS No. 1195765-45-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01723202 Active, not recruiting Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer Manisha Shah|National Comprehensive Cancer Network|Ohio State University Comprehensive Cancer Center November 7, 2012 Phase 2
NCT02672358 Not yet recruiting Non-Small-Cell Lung Cancer Novartis Pharmaceuticals|Novartis October 2017 Phase 2
NCT02447939 Withdrawn Melanoma GlaxoSmithKline May 2017 Phase 1
NCT02967692 Not yet recruiting Melanoma Novartis Pharmaceuticals|Novartis February 2017 Phase 3
NCT02858921 Not yet recruiting Melanoma Melanoma Institute Australia|Merck Sharp & Dohme Corp.|Novartis February 2017 Phase 2
NCT03026517 Recruiting Melanoma Memorial Sloan Kettering Cancer Center|Massachusetts General Hospital|Weill Medical College of Cornell University January 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Tags: buy Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) supplier | purchase Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) cost | Dabrafenib (GSK2118436) manufacturer | order Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID